2022年靶向放射性核素治疗试验概述。
A brief overview of targeted radionuclide therapy trials in 2022.
作者信息
Healy Aidan, Ho Elaine, Kuo Phillip, Zukotynski Katherine
机构信息
California Northstate University College of Medicine, California Northstate University, Sacramento, CA, United States.
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
出版信息
Front Nucl Med. 2023 Jun 23;3:1169650. doi: 10.3389/fnume.2023.1169650. eCollection 2023.
There is a growing use of radionuclide therapy for the medical care of oncology patients, where radioactive pharmaceuticals are used to target and treat various cancer types. This paper provides a brief overview illustrating the spectrum of ongoing and recently completed radionuclide therapy clinical trials in oncology. The trials selected highlight the potential of radionuclide therapies to provide a promising treatment option across a spectrum of cancer patients, while also discussing the importance of patient selection and monitoring, as well as potential side effects and safety concerns. Ultimately, the results of these trials will be crucial in determining the future use of radionuclide therapies in cancer treatment.
放射性核素疗法在肿瘤患者医疗护理中的应用日益广泛，在此过程中，放射性药物被用于靶向治疗各种类型的癌症。本文简要概述了正在进行的以及最近完成的肿瘤学放射性核素疗法临床试验的范围。所选取的试验突出了放射性核素疗法为各类癌症患者提供有前景治疗选择的潜力，同时也讨论了患者选择与监测的重要性，以及潜在的副作用和安全问题。最终，这些试验的结果对于确定放射性核素疗法在癌症治疗中的未来应用至关重要。
Zotero 插件